ClinicalTrials.gg
CompletedNCT02528266Updated Jun 13, 2018

Surgical Treatment of Symptomatic Neuroma "Stop Neuroma"

An interventional study of Nerve Capping Device in Neuroma, sponsored by Polyganics BV. Completed at 7 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-06-13.

Sponsored by Polyganics BV · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

This study is conducted to clinically assess safety and performance of the Polyganics nerve capping device for the treatment of symptomatic neuroma. There is sufficient clinical experience with regard to the safety of the commercially available nerve guide, NEUROLAC®. This new nerve capping device is identical in material and manufacturing. The exception is in design, where NEUROLAC® has two open ends, the nerve capping device has one closed (sealed) end. This study will be conducted to obtain data on the clinical performance of the capping device's ability to isolate the nerve end, resulting in a reduction of pain of experienced from the symptomatic neuroma and prevention of the reoccurrence of a symptomatic neuroma.

02

Conditions studied

  • Neuroma

Browse trials for

03

In context

Neuroma

55 studies on the registry are indexed under Neuroma; 10 are open to participants now.

This study's enrollment of 10 is below the median of 34 across 36 interventional studies indexed under Neuroma.

Browse Neuroma studies →

Lead sponsor

Polyganics BV is the lead sponsor of 7 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects will be eligible according to the following criteria:

  1. Subjects who are able to provide a written prior to participating in the clinical investigation.
  2. Subjects who are > 18 years year old.
  3. Subjects with a diagnosis of symptomatic primary or secondary end-neuroma.
  4. Symptomatic neuroma located on the upper limb between the metacarpophalangeal (MCP) joints to shoulder.
  5. Symptomatic neuroma confirmed by pain relief following a 10min ±2min nerve block with Xylocaine (Lidocaine) - Pain relief defined as any reduction in VAS questionnaire score.
  6. Subjects with history of pain in the area of the end-neuroma for at least 6-months.
  7. Subjects with a positive Tinel's sign.

Exclusion criteria

Exclusion Criteria:

Subjects who meet any of the following criteria will be excluded from participation:

  1. Inability to comply with the clinical investigation follow-up or other clinical investigation requirements.
  2. Subjects who are pregnant or intend to become pregnant during the duration of the clinical investigation or subjects who are not using appropriate .
  3. Subjects who have had historical radiotherapy in the area of the end-neuroma.
  4. Symptomatic neuroma located proximally from the shoulder or distally from MCP joints.
  5. Subjects not willing to follow post-surgery protocols (e.g. avoiding pressure on the implant zone).
  6. Subjects is involved in another pain study.
  7. Subjects who have a known allergy to anesthetic agent or bioresorbable copolyester Poly(68/32[15/85 D/L] Lactide-Ԑ-Caprolactone) (PLCL).
  8. Subjects with a symptomatic neuroma that underwent surgical treatment for pain management on two or more occasions.
  9. Insufficient soft tissue at the end-neuroma site to cover the device.
  10. patients, or patients with planned immunosuppressive therapy within 12-month following the study procedure.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Nerve Capping Device

    Implant with the experimental device

    Device: Nerve Capping Device

Interventions

  • DeviceNerve Capping Device
06

What researchers measure

Primary outcomes

  1. Safety data (Serious adverse events )

    Serious adverse events related to the investigation device as determine by independent expert.

    Time frame: 6 weeks

  2. Effectiveness (VAS score)

    Pain caused by symptomatic end-neuroma: VAS score (0-100 / no pain - unbearable pain) at 6-week follow-up compared to score at baseline.

    Time frame: 6 weeks

  3. Effectiveness (QuickDASH score)

    Pain caused by symptomatic end-neuroma: QuickDASH score (30 items scored 1-5) at 6-week follow-up compared to score at baseline.

    Time frame: 6 weeks

  4. Effectiveness (Quantity and class of pain medication used)

    Quantity and class of pain medication used for the end-neuroma pain at 6-week follow-up compared to baseline

    Time frame: 6 weeks

Secondary outcomes

  1. Safety (Rate of serious adverse device effects)

    Rate of serious adverse device effects as determined by the physician and independent expert. * Reduction of pain caused by symptomatic neuroma after 3 months, 6 months and 12 months following the procedure, as compared to pain before the procedure. * Improvement of quality of life at 3 months, 6 months and 12 months follow-up, as compared to the quality of life before the procedure. * ≤20% recurrence of symptomatic neuroma within 12 months. * Reduction of pain medication used to treat neuroma pain at 3 months, 6 months and 12 months, as compared to the quantity pain medication used for the neuroma pain before the procedure.

    Time frame: 3, 6 and 12 months

  2. Effectiveness (VAS score)

    Pain caused by symptomatic end-neuroma: VAS score (0-100 / no pain - unbearable pain) compared to score at baseline.

    Time frame: 3, 6, 12 months

  3. Effectiveness (QuickDASH score)

    Pain caused by symptomatic end-neuroma: QuickDASH score (30 items scored 1-5) compared to score at baseline.

    Time frame: 3, 6, 12 months

  4. Effectiveness (DN4 score)

    Pain caused by symptomatic end-neuroma: DN4 score (10 y/n items characterising pain) compared to score at baseline.

    Time frame: 6 weeks, 3, 6, 12 months

  5. Effectiveness (Elliot score)

    Pain caused by symptomatic end-neuroma: Elliot score (5 items rated 0 (no pain) to 4 (pain intolerable)) compared to score at baseline.

    Time frame: 6 weeks, 3, 6, 12 months

  6. Effectiveness (Quantity and class of pain medication used)

    Quantity and class of pain medication used for the neuroma pain at 3, 6 and 12 months

    Time frame: 3, 6, 12 months

  7. Rate of recurrence of symptomatic neuroma

    defined as daily pain combined with increased used of pain medication compared to baseline and no improvement in QuickDASH score, but pain is relieved with Xylocaine nerve block.

    Time frame: 12 months

Other outcomes

  1. Usability (User Device Handling Questionnaire)

    Ease of placement of the device assessed via User Device Handling Questionnaire.

    Time frame: Day 0

07

Study locations

7 sites
  • Strasbourg University Hospitals
    Strasbourg, F-67493, France
  • Haga Hospital
    Den Haag, 2545 CH, Netherlands
  • Albert Schweitzer Hospital
    Dordrecht, 3318 AT, Netherlands
  • UMCG
    Groningen, 9713GZ, Netherlands
  • Martini Hospital Groningen
    Groningen, 9728 NT, Netherlands
  • MC Groep
    Lelystad, 8233AA, Netherlands
  • MUMC
    Maastricht, 6229 HX, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Mar 2018, 26 months.

Of 21 interventional studies with no phase under Neuroma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 48. This study's 26 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 13, 2015
First posted
Aug 19, 2015
StartActual
Jan 2016
Primary completionActual
Mar 30, 2018
CompletionActual
Mar 30, 2018
Last update
Jun 13, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 13, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02528266
Lead sponsor
Polyganics BV
Responsible party
Sponsor
First posted
Aug 19, 2015
Start date
Jan 2016
Primary completion
Mar 30, 2018
Completion
Mar 30, 2018
Last update
Jun 13, 2018

Study contacts

Betty IJmker, MSc
study chair · Polyganics BV

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion